NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Demo Report

Report Issued 04/21/2022 16:23
Last Report Issued 07/28/2017 11:29

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 0649SP
Patient ID 0649SP
Chain 17001502
DOB Not Given
Sex Not Given
Workorder 17001502

Received 07/28/2017

Lab ID 17001502-001
Matrix Serum or Plasma
Patient Name 0649SP
Patient ID 0649SP
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
0649SP Methotrexate, Serum/Plasma				
Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)				
Methotrexate	None Detected	umol/L	0.0088	

Synonym(s): 4-Amino-10-methylfolic acid; Amethopterin; Methylaminopterin; MTX; Rheumatrex®; Trexall®

Cancer patients: 50 mg oral doses each hour for 16 hours achieved peak plasma concentrations after the last dose averaging 8.4 umol/L; the same dose given by 16 hour intravenous infusion resulted in an average plasma concentration of 9.9 umol/L at the end of the infusion.

Therapeutic monitoring is generally performed to ensure that plasma concentrations are below 1 umol/L at 48 hours after an infusion, or below 0.1 umol/L at 72 hours.

In patients diagnosed with psoriasis, the plasma median level was 0.095 umol/L at week 13 following a 7.5 mg weekly dose divided into three 2.5 mg doses given every 12 hours. In this same study, the plasma median level was 0.157 umol/L at week 13 following a 15 mg

Results for sample 17001502-001 are continued on next page

NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Lab ID 17001502-001
Matrix Serum or Plasma
Patient Name 0649SP
Patient ID 0649SP

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes

weekly dose divided into three 5 mg doses given every 12 hours.

Rheumatoid Arthritis (RA) patients:
A single 10 mg intramuscular dose produced an average peak concentration of 0.77 umol/L that declined with an average elimination half-life of 8.1 hours.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.